Relief Therapeutics Holding SA
· ISIN: CH1251125998
· EQS - Company News
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor
Smart tools for smart investors can be found in our Tools section
Corporate News Relief Therapeutics Holding SA
In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
This might be interesting for you as well
11 February 2025 07:00AM
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
Relief Therapeutics Holding SA
/ Key word(s): Patent
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
11.02.2025 / 07:00 CET/CEST
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
Patent Secures Protection for RLF-TD011 in Epidermolysi...
Relief Therapeutics Holding SA
22 January 2025 07:00AM
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE® Rights ex-USSale of GOLIKE® Rights Outside the U.S. to Nutrisens
Relief to Focus on R&D of Pipeline Assets and Licensing for Commercialized Products
GENEVA (JAN. 22, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharm...
Relief Therapeutics Holding SA
27 December 2024 07:00AM
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
Relief Therapeutics Holding SA
/ Key word(s): Merger
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
27.12.2024 / 07:00 CET/CEST
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
GENEVA (DEC. 27, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY)...
Relief Therapeutics Holding SA
16 December 2024 07:00AM
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
Relief Therapeutics Holding SA
/ Key word(s): Study results
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
16.12.2024 / 07:00 CET/CEST
Relief Therapeutics Announces Final Readout of PKU GOLIKE® Clinical Trial
Clinical Trial Demonstrates Superior Metabolic Control During Prolonged Fasting in PK...
Relief Therapeutics Holding SA
13 December 2024 11:00PM
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
Company to Maintain SIX Swiss Exchange Listing, U.S. ADR Program, and U.S. OTCQB Quotation
GENEVA (DEC. 13, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering inn...
Relief Therapeutics Holding SA
11 November 2024 07:00AM
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
GENEVA (NOV. 11, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, t...
Relief Therapeutics Holding SA
04 November 2024 07:00AM
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
GENEVA (NOV. 4, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced i...
Relief Therapeutics Holding SA
29 October 2024 07:00AM
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
Relief Therapeutics Holding SA
/ Key word(s): Miscellaneous
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
29.10.2024 / 07:00 CET/CEST
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
GENEVA (OCT. 29, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, O...
Relief Therapeutics Holding SA
25 October 2024 07:00AM
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
New Study Results Indicate Superior Absorption of RLF-OD032 in Fasted State Compared to KUVAN®, Potentially Enabling Flexible Dosing Options
GENEVA (OCT. 25, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a b...
Relief Therapeutics Holding SA
21 October 2024 07:00AM
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
GENEVA (OCT. 21, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, un...
Relief Therapeutics Holding SA
08 October 2024 07:00AM
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
GENEVA (OCT. 8, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare disea...
Relief Therapeutics Holding SA
04 October 2024 07:00AM
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
GENEVA (OCT. 4, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseas...
Relief Therapeutics Holding SA
23 September 2024 07:00AM
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
GENEVA (SEPT. 23, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it will r...
Relief Therapeutics Holding SA
23 September 2024 07:00AM
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
GENEVA (SEPT. 23, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it will r...
Relief Therapeutics Holding SA
More Relief Therapeutics Holding SA related information
| Type | Total | Last | Made by | Go to |
|---|---|---|---|---|
| Corporate Research | 0 | - | - | Corporate Research |
| Directors Dealings | 0 | - | - | DD |
| Short Seller (DE) | 0 | - | - | SSR (DE) |
| Short Seller (UK) | 0 | - | - | SSR (UK) |
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.
v.07062023 EN